Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

Key Points

• Danish pharmaceutical company Novo Nordisk plans to cut 9,000 jobs to streamline operations and enhance focus on growth in obesity and diabetes medications.
• This restructuring represents an 11% reduction of the company's workforce and aims to save approximately 8 billion Danish krone ($1.25 billion) by the end of 2026.
• The job cuts will begin immediately, with affected employees notified in accordance with local labor laws, as Novo Nordisk seeks to stay competitive in a consumer-driven obesity market.
• The company, now led by CEO Mike Doustdar, is responding to increased competition, particularly from Eli Lilly's weight-loss drugs, after previously seeing a surge in market capitalization.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the company's focus on growth opportunities in obesity and diabetes medications.

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.

The streamlining would save 8 billion Danish krone ($1.25 billion) by the end of 2026, savings that are to be redirected to diabetes and obesity, including research and development, the company said. Novo Nordisk also makes Ozempic, a diabetes drug that also can result in weight loss.

The company said implementation of the job cuts would begin immediately and that it would let the affected employees know over the next few months depending on local labor rules. The company, which is based in Bagsvaerd just outside Copenhagen, has 78,400 workers.

“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven,” said President and CEO Mike Doustdar. "Our company must evolve as well. This means instilling an increased performance-based culture, deploying our resources ever more effectively, and prioritizing investment where it will have the most impact — behind our leading therapy areas.”

Doustdar became CEO in May after his predecessor, Lars Fruergaard Jorgensen, left the company after the share price fell and as the company faced competition from weight-loss drugs from competitor Eli Lilly. Shares had skyrocketed after the introduction of Wegovy and Ozempic, which are both based on the same basic ingredient, semaglutide.

At the peak, the company’s market capitalization — or the combined price of all its shares — exceeded Denmark’s annual gross domestic product and made it Europe’s most valuable company.